{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:41:40Z","timestamp":1769222500780,"version":"3.49.0"},"reference-count":41,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"MD Anderson Cancer Center Support Grant","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]},{"name":"National Cancer Institute Award","award":["P01 CA049639"],"award-info":[{"award-number":["P01 CA049639"]}]},{"name":"Italian Association for Cancer Research Grant","award":["IG-10092"],"award-info":[{"award-number":["IG-10092"]}]},{"name":"Italian Association for Cancer Research Grant","award":["IG-14249"],"award-info":[{"award-number":["IG-14249"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:p>Long\u2010term efficacy and safety of bosutinib (\u22654 years follow\u2010up from last enrolled patient) were evaluated in an ongoing phase 1\/2 study in the advanced leukemia cohort with prior treatment failure (accelerated\u2010phase [AP, <jats:italic>n =<\/jats:italic> 79] chronic myeloid leukemia [CML], blast\u2010phase [BP, <jats:italic>n =<\/jats:italic> 64] CML, acute lymphoblastic leukemia [ALL, <jats:italic>n =<\/jats:italic> 24]). Fourteen AP, 2 BP, and 1 ALL patient remained on bosutinib at 4 years (vs. 38, 8, 1 at 1 year); median (range) treatment durations: 10.2 (0.1\u201388.6), 2.8 (0.03\u201355.9), 0.97 (0.3\u201389.2) months. Among AP and BP patients, 57% and 28% newly attained or maintained baseline overall hematologic response (OHR); 40% and 37% attained\/maintained major cytogenetic response (MCyR) by 4 years (most by 12 months). In responders at 1 versus 4 years, Kaplan\u2010Meier (KM) probabilities of maintaining OHR were 78% versus 49% (AP) and 28% versus 19% (BP); KM probabilities of maintaining MCyR were 65% versus 49% (AP) and 21% versus 21% (BP). Most common AEs (AP, BP) were gastrointestinal (96%; 83%), primarily diarrhea (85%; 64%), which was typically low grade (maximum grade 1\/2: 81%; 59%) and transient; no patient discontinued due to diarrhea. Serious AEs occurred in 44 (56%) AP and 37 (58%) BP patients, most commonly pneumonia (<jats:italic>n =<\/jats:italic> 9) for AP and pyrexia (<jats:italic>n =<\/jats:italic> 6) for BP; 11 and 13 died within 30 days of last dose (2 considered bosutinib\u2010related [AP] per investigator). Responses were durable in \u223c50% AP responders at 4 years (\u223c25% BP patients responded at year 1, suggesting possible bridge\u2010to\u2010transplant role in BP patients); toxicity was manageable.Am. J. Hematol. 90:755\u2013768, 2015. \u00a9 2015 The Authors. American Journal of Hematology Published by Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24034","type":"journal-article","created":{"date-parts":[[2015,6,2]],"date-time":"2015-06-02T22:56:53Z","timestamp":1433285813000},"page":"755-768","source":"Crossref","is-referenced-by-count":72,"title":["Long\u2010term efficacy and safety of bosutinib in patients with advanced leukemia following resistance\/intolerance to imatinib and other tyrosine kinase inhibitors"],"prefix":"10.1002","volume":"90","author":[{"given":"Carlo","family":"Gambacorti\u2010Passerini","sequence":"first","affiliation":[{"name":"Department of Internal Medicine University of Milano\u2010Bicocca Monza Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia Division of Cancer Medicine University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong\u2010Wook","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Hematology Seoul St. Mary's Hospital Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna J.","family":"Khoury","sequence":"additional","affiliation":[{"name":"Division of Hematology Winship Cancer Institute of Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna G.","family":"Turkina","sequence":"additional","affiliation":[{"name":"Hematology Research Center Moscow Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[{"name":"Clinic for Oncology Hematology and Stem Cell Transplantation Universit\u00e4tsklinikum Aachen, RWTH Aachen  Germany"},{"name":"Oncology Hematology and Stem Cell Transplantation Universit\u00e4tsklinikum Hamburg\u2010Eppendorf Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Matczak","sequence":"additional","affiliation":[{"name":"Pfizer New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Bardy\u2010Bouxin","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Pfizer Cambridge Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Turnbull","sequence":"additional","affiliation":[{"name":"Pfizer Cambridge Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Leip","sequence":"additional","affiliation":[{"name":"Pfizer Cambridge Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia Division of Cancer Medicine University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-3-199908030-00008"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(03)70045-6"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004325"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21032"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3530"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3547"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25123"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-10-200305200-00010"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.84"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8154"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.3339"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-186817"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083196"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3785"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-261586"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-013-0234-8"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-012-0247-7"},{"key":"e_1_2_7_22_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Acute Lymphoblastic Leukemia. Version 3.2013.Fort Washington PA:National Comprehensive Cancer Network."},{"key":"e_1_2_7_23_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Version 2.2014.Fort Washington PA.National Comprehensive Cancer Network."},{"key":"e_1_2_7_24_1","unstructured":"Bosulif: EPAR Product Information.London United Kingdom: European Medicines Agency."},{"key":"e_1_2_7_25_1","unstructured":"Pfizer Inc. BOSULIF\u00ae. New York NY: Pfizer Inc.;2014."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355594"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23728"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-513937"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390120"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046888"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.323"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.221"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8853"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23338"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10822"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.143"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11863"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404827"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404603"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-012-0247-7"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.160"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24034","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24034","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24034","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.24034","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:55:01Z","timestamp":1695570901000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1002\/ajh.24034"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24034","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}